Table 2 Adjusted odds ratios (ORs) and confidence intervals (CIs) for oral glucocorticoid use among cases and controls
Controls a | All bladder cancers b | ||
|---|---|---|---|
n =1083 | n =786 | Adjusted OR c (95% CI) | |
Glucocorticoid use | |||
No use | 1032 | 725 | 1.00 (reference) |
Both oral and inhaled | 9 | 11 | 2.17 (0.87–5.42) |
Oral only | 42 | 50 | 1.78 (1.15–2.76) |
Inhaled only | 32 | 38 | 1.52 (0.92–2.51) |
Oral glucocorticoid use d | |||
No | 1032 | 725 | 1.00 (reference) |
Yes | 51 | 61 | 1.85 (1.24–2.76) |
Former | 33 | 35 | 1.50 (0.91–2.48) |
Current | 17 | 21 | 2.18 (1.11–4.28) |
Total duration of oral glucocorticoid use d | |||
No use | 1032 | 725 | 1.00 (reference) |
⩽2 years | 38 | 46 | 1.87 (1.18–2.96) |
2–5 years | 8 | 7 | 1.29 (0.50–3.64) |
>5 years | 4 | 8 | 3.39 (0.98–11.74) |
Reason for oral glucocorticoid use e | |||
No use | 1032 | 725 | 1.00 (reference) |
Respiratory conditions and asthma | 15 | 16 | 1.73 (0.83–3.60) |
Musculoskeletal and connective tissue disease | 20 | 21 | 1.40 (0.74–2.68) |
Neoplasm | 1 | 4 | 3.51 (0.39–31.90) |
Allergy | 3 | 9 | 7.39 (1.93–28.29) |
Gastrointestinal disease | 5 | 5 | 2.10 (0.57–7.66) |
Other | 10 | 3 | 0.46 (0.12–1.70) |
